AllDocs -> cancers

ADENOVIRAL GENE THERAPY FOR OVARIAN CANCER Anna Kanerva Cancer Gene Therapy Group Rational Drug Design Program and Department of Obstetrics and Gynecology Helsinki University Central Hospital and Department of Oncology Helsinki University Central Hospital University of Helsinki Finland Academic Dissertation To be publicly discussed with permission of the Faculty of Medicine of the University of Helsinki, in Biomedicum Lecture Hall 3, Haartmaninkatu 8, Helsinki, on the 21 st of May 2004, at 12 noon. Helsinki 2004 Page 2 SUPERVISED BY Docent Akseli Hemminki, M.D., Ph.D. Cancer Gene Therapy Group, Rational Drug Design Program, University of Helsinki and Department of Oncology, Helsinki University Central Hospital Finland REVIEWED BY Professor ...

Pacific Ovarian Cancer Research Consortium (POCRC) Advocate Quarterly Meeting Saturday, September 29, 2001 9:00 AM - 1:00 PM Minutes Introductions: Sheryl Eisenbarth, POCRC Patient Advocacy Coordinator, started the meeting by inviting each advocate to introduce herself and share why they were part of the POCRC advocate group. It was decided that each meeting will begin with an “Advocate in Action” story. Ovarian Cancer National Alliance (OCNA) Advocacy Conference: Shirley Inveen shared her experience at the OCNA Conference “ Ovarian Cancer : Silent No More” held 9/19-22, 2001 in Indianapolis, IN. Shirley had to leave her Gig Harbor home at 3:00 AM in the morning to catch her flight and represent us at the conference! Free webcasts of the conference can be viewed at www.cancereducation.com . Sessions included cancer genetics, new and promising treatment therapies, prolonging ...

September 2003, Vol. 32 No. 5 661 Bowel Surgery for Epithelial Ovarian Cancer —Y N Chia et al Bowel Surgery for Epithelial Ovarian Cancer – An Early Case Series Y N Chia,* MBBS, MRCOG (UK) , E H Tay,** M Med (O&G), MRCOG (UK), DGO (Aust-NZ) , D M O Cheong,*** FAMS, MBBS, FRCS (Glas) , K W Eu,**** FAMS, FRCS (Edin), M Med (Surg) , J Low, + FAMS, M Med (O&G), MRCOG (UK) , T H Ho, ++ FAMS, M Med (O&G), FRCOG (Lond) , K L Yam, +++ FAMS, M Med (O&G), FRCOG (Lond) Abstract Objectives: The aims of this study were to review our local experience with bowel surgery for epithelial ovarian cancer at the Gynaecological Cancer Centre, KK Women’s and Children’s Hospital, and to document the outcome of such surgery as well as their complication ...

del file contenuto in http://www.lynnecohenfoundation.org/donationform/donationform.doc . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:hisb1r10uUIJ:www.lynnecohenfoundation.org/donationform/donationform.doc+allintitle:+ovarian+cancer+filetype:pdf+OR++filetype:doc+OR+filetype:ppt+OR++filetype:xls+OR+filetype:rtf&hl=it&lr=lang_en Google non ?ollegato agli autori di questa pagina e non ?esponsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: allintitle ovarian cancer You can mail this donation form to: The Lynne Cohen Foundation PO Box 7128 Santa Monica, CA 90406-7128 Or, fax this donation form to: 310.571.9126 ...

ovarian cancer Resident Teaching Conference Speaker: Barbara Goff, MD Handout: Blanca Esmeralda Ochoa, MD April 17, 2003 OVARIAN CANCER * * Today?s RTC topic is on ovarian and testicular cancers only. Most ovarian tumors are benign, but these will not be addressed in this handout. I. BIOLOGY OF OVARIAN CANCER : There are three main types of ovarian cancer : Epithelialovarian cancer - Most common type of ovarian tumor (80%). It arises from the epithelial cells of the ovary and pelvic cavity (that?s why bilateral oopherectomy does not completely eliminate the possibility of developing ovarian cancer in people with family history of this condition). Ovarian germ cell tumors-Accounts for 5% of ovarian cancers and they tend to occur in girls and young women. They arise from the seed cells that form the eggs. Most ...

Kiwanis Island Pavilion Turn Lane Merritt Avenue SR 520 Eastbound (Northern most lane only) Sykes Creek Parkway (eastern most lane) NORTH Walk Turnaround Point X Run Turnaround Point Start/Finish Line Sandi Childers Ovarian Cancer Awareness Benefit - 5K-Run/3K-Walk Road Course John Hurdle Bridge

217 American Journal of Epidemiology Copyright © 2002 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 155, No. 3 Printed in U.S.A. Infertility and Ovarian Cancer Ness et al. Infertility, Fertility Drugs, and Ovarian Cancer : A Pooled Analysis of Case- Control Studies Roberta B. Ness, 1 Daniel W. Cramer, 2 Marc T. Goodman, 3 Susanne Krûger Kjaer, 4 Kathy Mallin, 5 Berit Jul Mosgaard, 6 David M. Purdie, 7 Harvey A. Risch, 8 Ronald Vergona, 1 and Anna H. Wu 9 Controversy surrounds the relations among infertility, fertility drug use, and the risk of ovarian cancer . The authors pooled interview data on infertility and fertility drug use from eight case-control studies conducted ...

T he discoveries of BRCA1 and BRCA2, genes associated with hereditary breast can- cer, were hailed as among the most significant advances in modern medical science. It quickly became evident that these same genes con- tributed to hereditary ovarian can- cer. Soon after they were cloned, testing for mutations in BRCA1 (lo- cated on autosome 17) and BRCA2 (located on autosome 13) became available (Figure 1). Only an esti- mated 7% of breast cancers and up to 10% of ovarian cancers are hereditary. 1 The role of genetics in cancer is described in “How genes cause cancer ,” on page 4. This review explores the chal- lenges that the obstetrician-gynecol- ogist faces in determining which pa- tients might benefit from testing for mutations in BRCA1 and BRCA2, counseling these women about the pros and cons of screening, and ...

Analysis of MLH1 and MSH2 Expression in Ovarian Cancer before and after Platinum Drug-based Chemotherapy 1 Goli Samimi, 2 Daniel Fink, Nissi M. Varki, Amreen Husain, William J. Hoskins, David S. Alberts, and Stephen B. Howell Biomedical Sciences Program [G. S.], the Department of Medicine [S. B. H., N. M. V.], and the Cancer Center, University of California, San Diego, La Jolla, California 92093; Department of Gynecology, University of Zurich, Zurich, Switzerland 8091 [D. F.]; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021 [A. H., W. J. H.]; and Arizona Cancer Center, University of Arizona, Tucson, Arizona 85721 [D. S. A.] ABSTRACT Preclinical studies have demonstrated a relationship between DNA mismatch repair (MMR) status and sensitiv- ity to cisplatin and carboplatin. ...

NIH Consensus Statement Volume 12, Number 3 April 5–7, 1994 NATIONAL INSTITUTES OF HEALTH Office of the Director Ovarian Cancer : Screening, Treatment, and Followup Page 2 About the NIH Consensus Development Program NIH Consensus Development Conferences are convened to evaluate available scientific information and resolve safety and efficacy issues related to a biomedical technology. The resultant NIH Consensus Statements are intended to advance understanding of the technology or issue in question and to be useful to health professionals and the public. NIH Consensus Statements are prepared by a nonadvocate, non-Federal panel of experts, based on (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session; (2) questions and statements from conference attendees during open ...

Donna Karan, Charla Lawhon and invite you to S u p e rS a t u r d ay 6 to benefit THE OVARIAN CANCER RESEARCH FUND SATURDAY, JULY 26, 2003, 1 P.M. - 6 P.M. (EXCLUSIVE PREVIEW SHOPPING NOON - 1 P.M.) AT NOVA’S ARK PROJECT, 60 MILLSTONE ROAD, WATER MILL, NY SHOP TILL YOU DROP at our world famous designer garage sale and enjoy the super kids’ carnival with rides and games galore, In Style photo booths, and arts & crafts. Plus, don’t miss the stellar raffle, delicious lunch, snacks and refreshments, live entertainment, and many more fun surprises! Grand Benefactor: Betty Crocker Kids’ carnival sponsor: Toys “R” Us Benefactors: The Group for Women, The Sandler Family Patron: Hamptons Magazine Benefit Committee CHAIRS: Patti and Harvey Cohen & Faith and Jeffrey Kogan; Fabien Baron and Malin Ericson, Loraine and Peter ...

Anaheim, CA 92807 1-800-222-9880 1268 N. Lakeview Ave. TECO DIAGNOSTICS CA 125 ( MICROTITER ASSAY ) Enzyme Immunoassay for the Quantitative Determination of Ovarian Cancer Antigen CA125 in Human Serum F OR IN VITRO D IAGNOSTIC U SE O NLY Store at 2 to 8 ° C. P ROPRIETARY AND C OMMON N AMES CA125 Enzyme Immunoassay I NTENDED U SE For the quantitative determination of the Cancer Antigen CA125 concentration in human serum. I NTRODUCTION Cancer Antigen 125 (CA125) is a surface antigen associated with epithelial ovarian cancer . In serum, CA125 is associated with a high molecular weight glycoprotein. Published studies ...

ACUTE LEUKEMIA AFTER THERAPY WITH ALKYLATING AGENTS FOR OVARIAN CANCER A Study of Five Randomized Clinical Trials M ARK H. G REENE , M. D., J OHN D. JR., SC. D., E. G REER , M. D., J OHN A. B LESSING , PH. D., AND A LON Abstract We evaluated the occurrence of acute leukemia (ANL) among 1399 women with ovarian cancer who were treated in five randomized clinical trials. Of the 1399 women, 998 had been treated with ing agents, and among these, 12 cases of ANL were observed; the expected number was 0.11. Ten patients with ANL had received and two ANL was not observed in 401 women who had been treated with surgery or radiation or both, without agents. The excess risk of ANL that was asso- ciated with alkylating-agent ...

P.O. Box 12504 - Arlington, Virginia 22219 Phone: (703) 346-3893 www.ovariancancercoalition.org Fax: (703) 476-1976 OGCC is a non-profit 501(c)(3) organization and contributions are tax deductible to the fullest extent allowed by law. OGCC’s tax id number is 54-2004729. A Partner of the Ovarian Cancer National Alliance/Ovar’coming Together The Ovarian & Gynecologic Cancer Coalition Of Greater Washington – “Rhonda’s Club” Schedule of Events May & June 2004 Monday, May 10, 2004, 6:30 to 8:30 p.m. Serum Proteomics and the Hottest News Direct from the Society of Gynecologic Oncologists (SGO) Featuring Dr. James Barter Fresh from the annual SGO meeting, Dr Barter will present serum proteomics and forecast how this will change clinical practice and our diagnostic and monitoring experiences. He will discuss ...

Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo Antonia E. Stephen* † , Peter T. Masiakos*, Dorry L. Segev*, Joseph P. Vacanti † , Patricia K. Donahoe*, and David T. MacLaughlin* ‡ *Pediatric Surgical Research Laboratories, and † Laboratory for Tissue Engineering and Organ Fabrication, Department of Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114 Contributed by Patricia K. Donahoe, December 28, 2000 Techniques of tissue engineering and cell and molecular biology were used to create a biodegradable scaffold for transfected cells to produce complex proteins. Mullerian Inhibiting Substance (MIS) causes regression of Mullerian ducts in the mammalian embryo. MIS also causes regression in vitro of ovarian tumor cell lines and ...

OVARIAN CANCER - All Sections OVARIAN CANCER What Is Cancer ? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer , they all start because of out-of-control growth of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, cells in most parts of the body divide only to replace worn-out or dying cells and to repair injuries. Because cancer cells continue to grow and divide, they are different from normal cells. Instead of dying, they outlive normal cells and continue to form new abnormal cells. Cancer cells develop because of damage to DNA. This substance is in every cell and directs all its activities. Most of the time when DNA becomes damaged, either the ...

H:\EVERYONE\SYSTEMIC\Chemo\Protocol\Gyne\GOBEP.doc GOBEP Page 1 of 4 BCCA Protocol Summary for Non-dysgerminomatous Ovarian Germ Cell Cancer Using Bleomycin, Etoposide, and Cisplatin Protocol Code GOBEP Tumour Group Gynecology Contact Physician Dr. Ken Swenerton ELIGIBILITY: • non-dysgerminomatous ovarian germ cell cancer • as an adjuvant, or for patients with low, intermediate or high risk according to the international consensus prognostic classification (based upon the more frequent experience with analgous testicular tumours). Adjuvant Criteria: Retroperitoneal lymph node dissection pathology demonstrating involvement estimated to be associated with > 50% risk of subsequent relapse: 5 or more nodes involved, any involved node greater than or equal to 2 centimeters in diameter, or involved lymph node with extracapsular ...

1 PhD Thesis: Ovarian function and uterine characteristics in long-term survivors of childhood cancer . By Elisabeth C. Larsen MD, PhD The Ph.D. thesis includes a review and 4 papers. The project was carried out at the Fertility Clinic, Rigshospitalet in the period from 2000 to 2003. The aim of the project was to provide a comprehensive knowledge of the reproductive late adverse effects that may occur following treatment of a malignancy in childhood. One hundred adult female survivors of childhood cancer and 21 controls of similar age participated in the research program. All patients had received radiotherapy and/or chemotherapy. Seventeen patients had developed ovarian failure following the anti-neoplastic treatment. Thirteen patients used oral contraception. Examination of 70 patients with spontaneous menstrual cycles revealed endocrine and sonographic evidence ...

l del file contenuto in http://sweb.uky.edu/~idacev0/mpa2003.ppt . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:S6v91KsXioAJ:sweb.uky.edu/~idacev0/mpa2003.ppt+allintitle:+ovarian+cancer+filetype:pdf+OR++filetype:doc+OR+filetype:ppt+OR++filetype:xls+OR+filetype:rtf&hl=it&lr=lang_en Google non è collegato agli autori di questa pagina e non è responsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: allintitle ovarian cancer Significant between-group differences were found only on the SOS ( =.164, p=.042), ICIAI Ethnic Group Behaviors scale ( =.205, p=.014), and ICIAI Ethnic Group Principles scale ( =.269, p=.001). ...

Copyright © 1998 by W.B. Saunders Company. All rights reserved. 342 A BASIC INFORMATION DESCRIPTION A malignant growth in the ovary that is likely to spread to other body parts and threaten life. It affects females of all ages but is most common after age 50. There are many dif- ferent types of ovarian cancer . Epithelial tumors account for the majority and are the most aggressive. Other ovarian cancers are slow growing or metastasized from other can- cers in the body. FREQUENT SIGNS AND SYMPTOMS Frequently no symptoms occur until the tumor becomes large. The earliest symptoms include: • Vague discomfort in the lower abdomen. • Gastrointestinal upsets. • Irregular menstrual periods. Later symptoms: • Deep voice. • Excessive hair growth. • Unexplained weight loss. • An enlarged, hard and sometimes tender mass in ...